/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
TORONTO, Feb. 13, 2017 /CNW/ - ProMIS Neurosciences Inc. ("ProMIS" or the "Company") is pleased to announce that it has completed a first closing of its non-brokered private placement in the amount of CDN$2,298,085.02 which, as a result of over-subscriptions, is greater than the CDN$2,030,000 offering amount announced on February 2, 2017.
To accommodate further demand, ProMIS is increasing the offering to a maximum of CDN$2,700,000 for a maximum of 18,620,700 units (the "Units") at $0.145 per Unit. The Company plans to close the balance of the increased offering by February 17, 2017.
In the first closing on February 10, 2017, the Company issued 15,848,863 Units, each consisting of one common share of the Company and one-half of a common share purchase warrant. Each whole warrant is exercisable into one common share at a price of $0.20 per share for 36 months. Also, in connection with the first closing, ProMIS paid finder's fees of $56,170 and will issue 311,379 finder warrants, each exercisable into one common share at a price of $0.17 per share for 36 months.
All securities issued are subject to a four month hold period under applicable provincial securities laws in Canada. The offering is subject to customary conditions, including TSX approvals.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at:
SOURCE ProMIS Neurosciences Inc.
For further information: NATIONAL Equicom: Abby Garfunkel, Tel. 403-218-2887, email@example.com; or contact: Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.firstname.lastname@example.org